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Dendritic cells treated with chloroquine modulate
experimental autoimmune encephalomyelitis
Rodolfo Thomé1, Luidy Kazuo Issayama1, Rosaria DiGangi, Andre Luis Bombeiro, Thiago Alves da Costa,
Isadora Tassinari Ferreira, Alexandre Leite Rodrigues de Oliveira and Liana Verinaud
Chloroquine (CQ), an antimalarial drug, has been shown to modulate the immune system and reduce the severity of
experimental autoimmune encephalomyelitis (EAE). The mechanisms of disease suppression are dependent on regulatory T cell
induction, although Tregs-independent mechanisms exist. We aimed to evaluate whether CQ is capable to modulate bone
marrow-derived dendritic cells (DCs) both phenotypically and functionally as well as whether transfer of CQ-modulated DCs
reduces EAE course. Our results show that CQ-treated DCs presented altered ultrastructure morphology and lower expression
of molecules involved in antigen presentation. Consequently, T cell proliferation was diminished in coculture experiments. When
transferred into EAE mice, DC-CQ was able to reduce the clinical manifestation of the disease through the modulation of the
immune response against neuroantigens. The data presented herein indicate that chloroquine-mediated modulation of the
immune system is achieved by a direct effect on DCs and that DC-CQ adoptive transfer may be a promising approach for
avoiding drug toxicity.
Immunology and Cell Biology (2014) 92, 124–132; doi:10.1038/icb.2013.73; published online 12 November 2013
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Dendritic cells (DCs) are antigen-presenting cells that have an
important role in activation and modulation of naı̈ve T lympho-
cytes.1–3 The modulation of T cell functions occurs during antigen
presentation, where DCs provide three signals: first, epitope–major
histocompatibility complexes are recognized by the T cell receptor;
second, co-stimulatory signals sent by the interaction of DCs’ CD80
and CD86 with CD-28 expressed by T cells; third, the cytokine milieu
created by DCs and other cells in the microenvironment.4,5 The
combination of these signals leads to T cell differentiation into Th1,
Th2, Th17 and Th9 effector CD4þ T cells.4,6–8 The functional and
phenotypical plasticity of DCs is dependent on the activation/
maturation status of these cells turning them an interesting
target for therapy studies.2,9–11 Indeed, the adoptive transfer of
in vitro-modulated DCs was able to reduce the severity of collagen-
induced arthritis, diabetes and experimental autoimmune
encephalomyelitis(EAE).12–16
Chloroquine (CQ), an antimalarial drug, has been used as an anti-
inflammatory agent in the control of rheumatic conditions.17–19
Although the mechanisms are not fully elucidated, CQ acts as a
weak base and passively diffuses through the cytoplasm toward the
lysosomes where it is retained by ionic trapping.20 It was previously
demonstrated that treatment of DCs with CQ inhibits antigen
processing and presentation in vitro in a pH-dependent manner.21–23
An increasing amount of evidence suggests that CQ also exerts its
effects through pH-independent mechanisms.24–27 Recently, we
showed that CQ administration ameliorates the clinical and
immunological parameters of EAE, a model for the human multiple
sclerosis.28
EAE is established after neuroantigen-specific effector T cells breaks
in the central nervous system (CNS) of mice.29 In the CNS, effector
T cells secrete a myriad of molecules that activates resident microglia
and recruits inflammatory leukocytes ultimately leading to
demyelination.30 The clinical sign of the EAE start as paw weakness
and progressively aggravate as the damage to the myelin sheath
increases, resulting in death.31 Therefore, the cellular immune
response in EAE must be restrained. In this context, DCs may be
modulated toward an anti-inflammatory profile. Our previous results
with CQ administration in EAE have indicated that both Treg-
dependent and -independent mechanisms are responsible for disease
suppression.28 We hypothesize that CQ also interferes with dendritic
cell maturation thus reducing the cellular response against
neuroantigens.
In this study, we evaluated the effect of CQ administration to DCs.
Our results showed that CQ treatment promotes alterations in the
expression of molecules related to antigen presentation as well as
morphological and functional changes after in vitro antigen stimula-
tion. We also observed that adoptive transfer of CQ-modulated DCs
ameliorated the clinical course of EAE by the downregulation
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of the immune response toward neuroantigens and reduction in the
glial reactivity and local inflammation. Collectively, our data suggest
that CQ exerts its suppressive effects by interfering with the function of
DCs and that adoptive transfer of CQ-treated DCs may be an
interesting approach for the modulation of inflammatory conditions,
such as EAE.
RESULTS
CQ treatment modulates bone marrow-derived DCs in vitro
The expression of major histocompatibility complex class II molecules
was significantly reduced in cultures of DCs treated with CQ
(Figure 1a). Similarly, the expression of CD80 and CD86 molecules
on DCs was reduced after the treatment with the drug at higher
concentrations—ranging from 25 to 100mM (Figure 1a). The mor-
phology of DCs after microbial challenge was altered in cells treated
with the drug compared with PBS-treated controls, such as reduction
on absolute size and dendropoiesis (Figure 1b). High CQ concentra-
tions exert toxic effects in vivo; in order to evaluate the possible
cytotoxic action of the drug, DCs were cultivated in the presence of
CQ at several doses. As shown in Figure 1c, the treatment with CQ
did not reduce the viability of DCs.
For functional analysis, DCs were treated with CQ, dexamethasone
or PBS (DC-CQ, DC-Dexa and DC-PBS, respectively) and cultivated
with CD4þ T cells in the presence of MOG35–55 peptide. The results
showed that T lymphocytes cultivated in the presence of DC-CQ
proliferated significantly less compared with cells cultivated with
other DCs (Figure 2a). It was previously observed that CQ admin-
istration promotes an increase in the expression of nitric oxide
synthase (NOS) in several cell types, interfering with renal function
and other NO-dependent mechanisms.32–34 However, in
macrophages, CQ treatment reduced the NO synthesis.35,36 There is
lack of evidences about NO production by CQ-treated DCs. In order
to solve this question, DCs were cultivated in the presence of
increasing doses of CQ and NO secretion was measured later.
Surprisingly, the results showed that there was a dose-dependent
augmentation in NO production by DCs (Figure 2b). The next goal
was to determine whether the higher production in NO was directly
influencing the T cell proliferation. Thus, DCs were treated with CQ
and cultivated with CD4þT cells in the presence of a NOS inhibitor,
L-NAME. The data obtained show that T cells cultured with DC-CQ
proliferated significantly less than cells cultivated with DC-PBS;
however, the treatment with L-NAME restored the proliferative
response of T cells from DC-CQ mixed cultures (Figure 2c).
Transfer of CQ-modulated DCs ameliorates EAE
The data presented here show that DCs are modulated by CQ in vitro.
The therapeutic usage of CQ-modulated DCs was investigated as well.
For that purpose, PBS- and CQ-treated DCs were adoptively
Figure 1 CQ treatment provokes phenotypical alterations in DCs. Bone marrow-derived DCs were treated with distinct CQ doses and stimulated with LPS
(1Zg ml1) for 18 h. (a) The mean fluorescence index (MFI) of MHC-II, CD86 and CD80 was reduced in CQ-treated cells (solid line) compared with the
PBS-treated ones (dotted line); **Po0.01 and ***Po0.001. (b) Scanning electron microscopy analysis showed that the treatment with CQ promoted
alterations in the structure of DCs. The figures are representative of three independent experiments. (c) The toxicity of CQ was also evaluated by MTT assay.
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transferred to naı̈ve mice and the development of EAE was mon-
itored. EAE was induced by immunization of mice with MOG35–55
peptide in an inflammatory context. Mice recipient of DC-PBS
presented reduction of body weight and development of severe
EAE, whereas the transfer of DC-CQ was capable to reduce the
clinical signs of the disease (Figures 3a and b, respectively). In all
experiments, DC-CQ-recipient mice presented lower cellular infiltra-
tion in the CNS in comparison with DC-PBS transferred and
untreated EAE-inflicted mice (Figure 3c). To assess the presence of
MOG-reactive cells in the periphery, EAE mice were killed and spleen
cells were cultivated in the presence of MOG35–55 peptide and whole
myelin basic protein. The cells were cultivated in the presence of
ovalbumin as a control of an unrelated antigen. The results showed
that spleen cells from DC-CQ-recipient EAE mice proliferated
significantly less compared with the DC-PBS transferred and
untreated EAE-inflicted mice in the presence of neuroantigens;
however, there were no statistical differences between groups regard-
ing the proliferation against ovalbumin (Figure 3d).
Transfer of CQ-modulated DCs reduces the glial reactivity
in the CNS
The transfer of CQ-modulated DCs reduced the clinical course of
EAE and was correlated with the lower T cell responsiveness in the
spleen. Inflammation in the CNS results in neurodegeneration. The
infiltration of inflammatory cells in the CNS of DC-CQþ EAE mice
was found reduced compared with the control groups, DC-PBS
transferred and untreated EAE mice (Figure 3c). Gliosis is the result of
the activation of the glial cells, comprising astrocytes, oligodendro-
cytes and microglia (Iba-1þ cells) after microenvironmental distur-
bances. The activation of astrocytes during inflammatory conditions
favors the tissue microglial response, which ultimately leads to
neuronal death.37 Astrocytes express the glial fibrillary acidic
protein (GFAP) upon stress. Due to its importance as a marker for
glial reactivity, the presence of GFAPþ cells was analyzed in the CNS
of EAE mice. The results showed that untreated and DC-PBS-
transferred EAE-inflicted mice had significantly higher frequency of
GFAPþ cells compared with the naı̈ve group, whereas the transfer of
DC-CQ was able to reduce the overall activation of astrocytes
(Figure 4). Interestingly, the frequency of Iba-1þ cells was found
significantly upregulated in both treatment groups compared with the
naı̈ve and untreated EAE, although the Iba-1 expression in the CNS
from DC-CQ-treated mice was significantly reduced compared with
the DC-PBS group.
Transfer of CQ-modulated DCs alters the gene expression in the
CNS of EAE mice
As adoptive transfer of CQ-modulated DCs was capable of reducing
the clinical manifestation of EAE and as mice recipient of DC-CQ
presented lower cellular infiltration in the CNS as well as reduced
activation of glial cells, the gene expression of inflammatory
mediators was investigated. The results indicated that although the
expression of TGF-b and IFN-g was not altered between groups, the
levels of IL-6 and IL-17 were found significantly reduced in CNS
tissue from mice recipient of CQ-modulated DCs compared with EAE
groups, both untreated and DC-PBS transferred. There was also an
increase in the expression of IL-10 in the spinal cords of DC-CQ-
recipient mice compared with all other groups (Figure 5). The
expression of FOXP3 in CNS from DC-CQ-transferred EAE mice
was found significantly elevated compared with healthy mice.
Collectively, the data presented here show that the reduction in
clinical outcome of EAE correlated with the downregulation of
inflammatory mediators in the CNS and in the periphery of the
immune system.
DISCUSSION
The development of new approaches in the treatment of autoimmune
diseases is a common feature in today’s research. It is known that
autoimmune diseases arise in uncontrolled inflammatory responses,
and that loss of self-tolerance is a key step in this process. Therefore,
therapies that restore either the control of inflammation or the
tolerance to self are desired. In this context, DCs are an interesting
target, because they can stimulate the generation of Tregs and control
inflammation.3,38 The present study shows that transfer of CQ-
modulated DCs reduces the clinical signs of EAE.
CQ, an antimalarial drug, has been used in the control of
rheumatic diseases as well.39,40 The mechanism of action resides in
the fact that CQ is a weak base that passively diffuses toward acidic
organelles, like the lysosomes.41,42 The rise of pH interferes with the
function of several enzymes and metabolic processes within
the cell.43,44 However, pH-independent mechanisms also occur, as
Figure 2 CQ treatment provokes functional alterations in DCs. Bone marrow-derived DCs were treated with CQ and stimulated with LPS (1Zg ml1) for
18 h. (a) DCs were treated either with dexamethasone (DC-Dexa, 50mM) or CQ (DC-CQ, 50mM) and stimulated with LPS (1Zg ml1) and then pulsed with
MOG35–55 peptide (10mg ml1) for 18 h. CD4þ T lymphocytes were isolated from spleens of naı̈ve mice using magnetic beads and cocultured with DCs
(1:1) for 96h in the presence of the antigen. The proliferation was evaluated by MTT. (b) The production of nitric oxide was determined by adding Griess
reagent on culture supernatants from DCs treated with CQ. (c) DCs were treated with CQ (DC-CQ, 50mM) and stimulated with LPS (1Zg ml1) and then
pulsed with MOG35–55 peptide (10mg ml1) for 18h. CD4þ T lymphocytes were isolated from spleens of naı̈ve mice using magnetic beads and cocultured
with BMDCs (1:1) for 96 h in the presence of the antigen and an NOS inhibitor (L-NAME, 1 mM). The proliferation was evaluated by MTT. Data are
representative of three independent experiments. *Po0.05.
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Figure 3 Adoptive transfer of CQ-treated DCs ameliorates EAE. DCs were treated with CQ (50mM) and LPS (1Zg ml1), and then pulsed with MOG35–55
peptide (10mg ml1) for 18 h and adoptively transferred (1.5106 cells per mouse) into C57BL/6 mice (n¼6 per group) before the induction of EAE. (a)
The weight variations were evaluated daily. (b) The clinical score of DCs-transferred and untreated EAE-inflicted mice was evaluated as well; ***Po0.001.
(c) The histological analysis of the spinal cords from DC-CQ-recipient mice showed mild infiltration of inflammatory cells than in DC-PBS recipient and
untreated EAE mice. (d) The spleens of naı̈ve, EAE and DC-transferred EAE (both DC-PBS and DC-CQ) mice were collected and total leukocytes (5105
per well) were cultured in the presence of MOG35–55 peptide, Myelin basic protein and Ovalbumin (10mg ml1, 50mg ml1 and 50mg ml1, respectively)
for 96 h. The proliferation was analyzed using the MTT method; *Po0.05. Data are representative of three independent experiments. Magnification of
histological sections: 200 (main) and 400 (details).
Figure 4 Microglia and astroglial response in EAE mice after DC transfer. DCs were treated with CQ (50mM) and LPS (1Zg ml1), and then pulsed with
MOG peptide (10mg ml1) for 18h and adoptively transferred (1.5106 cells per mouse) into C57BL/6 mice (n¼6 per group) before the induction of
EAE. The spinal cords of EAE mice were collected 14 days after immunization. Frozen thin sections (12mm) were made, fixed in formalin and the reactivity
sites were blocked with PBS-BSA 3%. GFAP and Iba-1 primary antibodies were added and treated with secondary antibodies conjugated with Cy2. The
sections were analyzed in epifluorescence microscope. The images were analyzed by ImageJ software and the integrated density of pixels was determined.
***Po0.001. Figures are representative of three independent experiments. Magnification: 200.
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the treatment with CQ interferes with the iron metabolism in
macrophages.27 The treatment of DCs with CQ was shown to
inhibit processing of antigens, which is pH-dependent.45
Interestingly, CQ administration favors the cross-presentation by
DCs and improves the development of adaptive immune responses
toward ovalbumin.22 We observed that the treatment of DCs with CQ
reduced the expression of molecules related to antigen presentation.
Likely, the treatment promoted ultrastructural changes in the
morphology of the cells. These observations suggest that the drug
has an anti-inflammatory effect. The lysosome dysfunction promoted
by CQ facilitates accumulation of cell debris and leads to cell death,
especially cells of the retinal pigment epithelium.41,46 We found that
CQ, in the doses tested in this study, has no toxic effect on DCs.
The maturation status of DCs defines the profile of activation of
T cells.47 Mature DCs express higher levels of class II
major histocompatibility complex and co-stimulatory B7 molecules,
whereas the immature/semi-mature phenotype produces intermediate
expression of these molecules.11 CQ does change the profile of DC
maturation phenotypically. Functionally, mature DCs stimulate the
differentiation of Th1, Th17 and Th2 T cells.48 Semi-mature DCs
induce the differentiation of naı̈ve T cells in regulatory T cells by
differentiated co-stimulation.47 Failure in antigen presentation leads
to improper activation of T cells. We observed that CQ-modulated
DCs failed to induce proliferation of CD4þ T cells in vitro. One could
argue that DCs, under the effect of CQ, do not process antigens.
However, in these set of experiments, DCs were pulsed with protein
peptide, which overcomes the need for lysosome-dependent antigen
degradation.
Previous reports showed that CQ stimulates the expression of
NOS isoforms.32–34 Although NO is believed to aggravate
neuroinflammation,49 its role as an immunomodulator has gained
attention. It was previously demonstrated that NO blockade favors
the development of antigen-specific response toward Listeria
monocytogenes and mycobacterial infection.50,51 It was also shown
that EAE is exacerbated in the absence of NO.52 Conversely, nitric
oxide stimulates the generation of Tregs while suppressing IL-17-
producing cells.52,53 In this context, the existence of TNF/iNOS-
producing ‘Tip’-DCs has been demonstrated.54 These DCs are
responsible for determinant spread in EAE, and are believed to have
an important role in neuroinflammation.55 Nevertheless, Tip-DCs
seem to limit the expansion of autoreactive T cells in experimental
autoimmune myocarditis.56 Thus, the dual role of Tip-DCs must
be better characterized in autoimmune conditions. Our results
showed that CQ stimulated NO production by DCs in a
dose-dependent manner and produced high amounts of TNF-a
after lipopolysaccharide stimulation (data not shown), which may
classify these cells as Tip-DCs. NO production, in our analysis,
seemed to have a role in the stimulation of T cell proliferation. We
Figure 5 Altered gene expression of inflammatory mediators in CNS tissue of DC-transferred mice. Mice received PBS- and CQ-treated DCs (1.5106 cells
per mouse) 3 days before EAE induction. The CNS tissue (brain and spinal cord) was removed at the peak of the disease. RNA was extracted, converted to
cDNA and the relative messenger RNA expression of IL-6, TGF-b, IL-17, IL-10, IFN-g and FOXP3 was determined by reverse transcriptase-PCR reactions in
naı̈ve, EAE and DC-transferred EAE (both DC-PBS and DC-CQ) mice. *Po0.05 and **Po0.01. Results are expressed as mean±standard error mean
(s.e.m.) for at least four animals from each group from two independent experiments.
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observed that the suppressive effect of CQ-modulated DCs was
abolished after L-NAME, an NOS inhibitor, treatment. These
observations suggest that the suppressive effects exerted by CQ-
modulated DCs are NO dependent.
The transfer of tolerogenic DCs is an interesting approach for the
control of chronic inflammation.13,57,58 However, it is unclear which
signals turn DCs into fully mature and which turn them
immunosuppressive.11 For instance, it was previously demonstrated
that vitamin D is an important regulator of DC function.59 Transfer
of vitamin D-modulated DCs was shown to reduce the clinical signs
of EAE through the expansion of regulatory T cells.16 Also, treatment
with apoptotic cells drives these cells into a permissive state, and that
transfer of apoptotic cell-induced tolerogenic DCs ameliorates the
course of EAE through the downmodulation of inflammatory
T cells.60 Several studies also showed that pathogen-derived
molecules interfere with DC maturation status, prompting them for
the use in the control of inflammatory conditions.58,61,62 We observed
that CQ reduces the expression of antigen-presentation molecules and
the functional profile of DCs in vitro. Thus, CQ administration induces
a semi-mature phenotype in DCs. In addition, the transfer of CQ-
modulated DCs reduced the clinical signs of EAE, a T cell-mediated
disease. The peripheral cellular response toward neuroantigens (both
MOG and myelin basic protein) was diminished as well as the
infiltration of inflammatory cells in the CNS. Interestingly, the
immune response toward ovalbumin, an unspecific antigen, was
maintained, which strongly suggests that the reduced response
generated after DC-CQ transfer is antigen/tissue specific.
The infiltration of leukocytes in the CNS promotes local
inflammation and may lead to neurodegeneration, in which the glial
reactivity is an important hallmark.63 Astrocytes, upon environmental
disturbances, express higher levels of the intermediary filament
GFAP in sites of nerve injury.64 Uncontrolled astrogliosis leads to
the formation of glia scars that are irreversible, also called
anisomorphic gliosis.65–67 We found an upregulation in the
expression of GFAP in EAE-inflicted mice both untreated and
treated with DC-PBS. Interestingly, mice that received CQ-
modulated DCs showed lower glial reactivity. The numbers of Iba-
1þ cells were similar between the treatment groups, which may
indicate: (1) the frequency of microglia does not dictate the course of
EAE, but their activation profile does; (2) the transferred DCs (which
may express Iba-168) migrated to the CNS; (3) both these phenomena
occur concurrently. In this context, we observed that the expression of
cytokines within the CNS was found altered in EAE-inflicted mice,
with an increase in regulatory IL-10 and reduced inflammatory IL-17
and IL-6 after transfer of DC-CQ. Our data support the hypothesis
that a change in the inflammatory status of the CNS toward an anti-
inflammatory profile is responsible for the amelioration observed in
the clinical course of DC-CQ-treated mice.
It is not yet clear the mechanism by which CQ exerts its
immunomodulatory effects on DCs. Although pH-dependent inter-
ference exists, recently it has been demonstrated that CQ interacts
with the mTOR pathway in MCF7 cancer cells.69 In DCs, it was
shown that manipulation of the mTOR signaling cascade facilitates
the antigen presentation in a Treg-inducing milieu while inhibiting
Th1/Th17 differentiation.70 In this context, more studies must be
conducted in order to solve whether CQ and mTOR pathway are
related in DCs modulation.
The chronic CQ usage has been shown to provoke collateral side
effects, including retinal toxicity.71–73 We demonstrated that low-dose
CQ administration is capable of reducing the clinical sign of EAE
through the stimulation of regulatory T cells.28 Although the
treatment period was brief and that the dose used was low, the
chances of retinal toxicity still exists in a chronic treatment regimen.
We propose that an alternative for the chronic consumption of the
drug is the modulation of DCs in vitro and its adoptive transfer. This
approach not only prevented toxicity of the drug but also reduced the
EAE severity in an antigen-specific manner. Other treatments
currently in use such as those with anti-inflammatory drugs and
monoclonal antibodies, although still important and necessary, act
promoting a general nonspecific suppression. In this sense, the
administration of CQ or CQ-modulated DCs together with classical
FDA-approved anti-inflammatory drugs/monoclonal antibodies may
reduce the doses of the medicines consumed by the patients, thus
decreasing the elevated costs of the multiple sclerosis treatment. In
addition, transfer of mitomycin C-treated DCs was able to reduce the
cellular response toward neuroantigens in vivo.12 In this study, the
authors showed that the in vitro modulation of DCs with a clinically
approved drug and its posterior adoptive transfer is an interesting
approach for the treatment of multiple sclerosis and EAE. Indeed, in
coculture experiments with patient’s mitomycin C-treated DCs and
effector T cells, the proliferation of the latter was inhibited, whereas
the dendritic cell immature phenotype was not reverted.
Collectively, our data indicate that CQ modulates DCs both
phenotypically and functionally. The adoptive transfer of CQ-modu-
lated DCs was able to reduce the clinical signs of EAE by the
downregulation of cellular immune response toward neuroantigens.
Consequently, the glial reactivity was diminished in the CNS of
mouse that received CQ-treated DCs and may have contributed to the
amelioration of disease course. Taken together, our data indicate that
adoptive transfer of CQ-modulated DCs may become an alternative
for the chronic consumption of the drug, thus avoiding toxicity.
METHODS
Mice
Six-to-eight week-old female C57BL/6 mice from the Multidisciplinary Center
for Biological Research, University of Campinas, were used in this study. Mice
were kept in specific-pathogen free condition, in a controlled temperature and
photoperiod environment, with autoclaved food and water ad libitum
throughout the experiment. The Institutional Committee (Comissão de Ética
no Uso de Animais–CEUA/UNICAMP; Protocol number 2687-1) approved
the protocols involving laboratory animals.
Generation of DCs, treatment and adoptive transfer
Bone marrow-derived precursors were used in the generation of DCs,
according to a previous report.74 Briefly, femurs were collected and the bone
marrow cells were flushed out with RPMI medium supplemented with 2-
mercaptoethanol (2 mM), fetal bovine serum (10% v-v) and gentamicin
(50mg ml1)–referred to as complete medium. 5 106 cells were seeded in
24-well culture plate containing complete medium supplemented with GM-
CSF (10Zg ml1). Fresh medium was added at days 3 and 6 of culture. This
culture method results in DC generation of 85–95% purity, assessed by flow
cytometry. DCs were used in transfer or coculture experiments. For adoptive
transfer experiments, DCs were treated with CQ (50mM, Sigma-Aldrich,
St Louis, MO, USA) or dexamethasone (50mM) for 18 h in the presence of
lipopolysaccharide from Escherichia coli O111:B4 (1Zg ml1, lipopolysacchar-
ide, Sigma-Aldrich) and pulsed overnight with 10mg mL1 of MOG35–55
peptide (Rheabiotec, Campinas, Brazil). PBS was added as a control reagent.
1.5 106 cells were adoptive transferred via intravenously by the retroorbital
route 3 days before EAE induction.
Coculture experiments
For the coculture experiments, 5 105 per well DCs treated as above were
seeded in flat-bottom 96-well plates. Splenocytes were enriched in lymphocytes
by centrifugation in Percoll gradient, following a previously published
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R Thomé et al
129
Immunology and Cell Biology
protocol.75 CD4þ T lymphocytes were isolated using Dynabeads following
manufacturer’s instructions (CD4þT cell isolation kit, Applied Biosystems,
Life Technologies, Austin, TX, USA). This protocol resulted in a purity of 90–
95% CD4þ T cell, confirmed through analysis by flow cytometry. 5 105 per
well CD4þ T cells were seeded together with DCs at a ratio of 1:1 (DC:T) in
200ml of complete RMPI medium containing MOG35–55 (MEVG-
WYRSPFSRVVHLYRNGK, 10mg ml1, Rheabiotec). As controls, CD4þ T
cells were grown in the absence of DCs. The plates were incubated at 37 1C for
96 h. For the evaluation of NO blockade, some cultures were conducted in the
presence of the NOS inhibitor, N (G)-nitro-L-arginine methyl ester (L-NAME,
1 mM, Sigma-Aldrich). After the incubation period, the cells were treated with
10ml of 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT,
5 mg ml1, Sigma-Aldrich) for 4 h and the formazan crystals dissolved with
100ml of isopropanol. Absorbances were read at 540 nm by spectrophotometer
(VersaMax, Molecular Devices, Sunnyvale, CA, USA).
NO dosage
Nitrite production was determined using the Griess reagent following a well-
established protocol.76,77
EAE induction and evaluation
EAE was induced and evaluated in mice according to a previously published
paper.28 Briefly, each mouse was injected with 100mg MOG35–55 (RheaBiotec)
emulsified with complete Freund́s adjuvant (CFA, Sigma). Pertussis toxin (Ptx,
Sigma) 200Zg was administrated via i.p. at 0 and 48 h after antigen challenge.
Clinical signs were followed and graded daily according to a score method,
were 0: no sign, 1: flaccid tail, 2: hind limbs weakness, 3: hind limbs paralysis,
4: hind paralysis and fore limbs weakness, 5: full paralysis/dead. At the
indicated time points after antigen challenge, mice were killed, spinal cords
were removed and snap frozen in OCT Tissue Tek; 12-mm thin slices were
made and stained with haematoxylin and eosin.
Immunofluorescence
Fourteen days after EAE induction, mice were killed and the spinal cords were
collected, snap frozen as mentioned above and 12-mm thin slices were made.
The reactive sites were blocked with phosphate buffer (0.1 M, pH7.2)-BSA 3%.
The cells were stained with purified rabbit anti-glial fibrillary acid protein
(GFAP, at a 1:1200 dilution, Dako, Glostrup, Denmark) and anti-Iba-1
antibodies (at a 1:1200 dilution, Dako). The reaction was treated with Cy2-
conjugated goat anti-rabbit immunoglobulin G (diluted 1:250, Vector) and
analyzed under epifluorescence microscope (Leica Microsystems Inc., Buffalo
Grove, IL, USA).
Scanning electron microscopy
1 106 DCs treated both with CQ or PBS were stimulated with lipopoly-
saccharide (1Zg mL1) and cultivated over glass coverslips for 18 h at 37 1C.
Cells were fixed (1 ml of a solution consisting of glutaraldehyde 2% and tannic
acid 1%) for 1 h. The post fixation was made in aqueous 1% osmium tetroxide
for 2 h. The material was dehydrated with series of ethanol and then brought to
the critical point with liquid CO2 (Balzers CPD 030) and covered with gold
bath (Sputter Coater Balzers SCD 050, Capovani Brothers Inc., Scotia, NY,
USA). Cells were viewed in a JEOL 5800LV scanning electron microscope.
Lymphoproliferative analysis
For the evaluation of antigen-specific proliferation, leukocytes were collected
from spleens of control and EAE-inflicted mice. Briefly, spleen were collected
aseptically and macerated with the aid of piston and sieve to prepare cellular
suspensions. Cells were treated with ACK lysis buffer (ammonium-chloride-
potassium) for 3 min and washed with complete RPMI medium. 5 105 cells
per well were seeded in 96 flat-well plates with 200ml of complete RPMI
medium containing 10mg ml1 of MOG35–55 (Rheabiotec) and incubated at
37 1C for 96 h. As control, cells were grown in the absence of antigen. After the
incubation period, the cultures were treated with 10ml of 3-(4,5-Dimethylthia-
zol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, 5 mg ml1, Sigma-Aldrich)
for 4 h and the formazan crystals dissolved with 100ml isopropanol.
Absorbances were read at 540 nm by spectrophotometer.
Reverse transcriptase PCR
The RNA was extracted from the samples with TRIzol reagent (Life
Technologies, Austin, TX, USA). RNA concentration was calculated by reading
the absorbance at 280 nm and the purity guaranteed by the ratio of 280/
260 nm (ratios ranging from 1.8 to 2.0 were used). One microgram of RNA
was converted to cDNA using High Capacity cDNA Reverse Transcription
kit following the manufactures recommendations (Life Technologies). Expres-
sion of IL-6 (Mm00446190_m1), IL-10 (Mm00439614_m1), IL-17
(Mm00439618_m1), IFN-g (Mm01168134_m1), TGF-b (Mm01178820_m1)
and FOXP3 (Mm00475162_m1) was analyzed in comparison with GAPDH
(Mm99999915_g1, housekeeping gene). Reverse transcriptase PCR reactions
were performed using Taqman reagents according to manufacturer’s recom-
mendations (Applied Biosystems).
Flow cytometry
For flow cytometry analysis, 1 106 cells were labeled with fluorochrome-
conjugated monoclonal antibodies. Cells were incubated with antibody cocktail
for 30 min at 4 1C and fixed with 1% formaldehyde. The antibodies used were
as follows: anti-CD11c/APC (clone N418), anti-major histocompatibility
complex-II/PECy7 (clone M5/114.15.2), anti-CD80/FITC (clone 16-10A1),
anti-CD86/PE (clone GL-1), all from eBioscience (San Diego, CA, USA).
50 000 events were acquired from each sample in flow cytometer (FACSCanto,
BD Biosciences, Franklin Lakes, NJ, USA) and analyzed in FlowJo 7.5 software
(Tree Star Inc., Ashland, OR, USA).
Statistical analysis
For clinical score and weight comparisons, collected data were analyzed by
two-way analysis of variance with Bonferroni post hoc test. Analyses between
two groups were performed by Student’s t-test. All analyses were performed
using GraphPad prism version 5.0 (GraphPad software, San Diego, CA, USA).
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